Emergent BioSolutions Files 8-K
Ticker: EBS · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, reporting, financials
TL;DR
Emergent BioSolutions filed a standard 8-K on Jan 14, 2025. No major news.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on January 14, 2025, to report other events and financial statements. The filing does not contain specific details about new material events or financial figures within the provided text, but indicates a standard reporting update.
Why It Matters
This filing serves as a routine update for investors and the public regarding Emergent BioSolutions' corporate activities and financial reporting status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or significant negative events.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 14, 2025.
What is the exact date of the earliest event reported?
The date of the earliest event reported is January 14, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 14-1902018.
What is the Standard Industrial Classification code for Emergent BioSolutions Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-14 08:13:13
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20250114.htm (8-K) — 29KB
- pressrelease_01142025.htm (EX-99.1) — 39KB
- imagea.jpg (GRAPHIC) — 7KB
- 0001367644-25-000010.txt ( ) — 210KB
- ebs-20250114.xsd (EX-101.SCH) — 2KB
- ebs-20250114_lab.xml (EX-101.LAB) — 22KB
- ebs-20250114_pre.xml (EX-101.PRE) — 13KB
- ebs-20250114_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 14, 2025, Emergent BioSolutions Inc. ("Emergent") issued a press release announcing an agreement with Hikma Pharmaceuticals Inc. ("Hikma") in which Emergent obtained commercial rights in the United States and Canada to Hikma's KLOXXADO (Naloxone HCl) Nasal Spray, an 8 mg naloxone agent. Under the terms of the agreement, Hikma will continue to manufacture KLOXXADO Nasal Spray 8 mg, which will be integrated into Emergent's proprietary NARCANDirect distribution network. A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on January 14 , 202 5 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: January 14, 2025 By: /s/ Richard S. Lindahl Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer